{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:40:51Z","timestamp":1768012851489,"version":"3.49.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.maturitas.2020.04.015","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T12:32:38Z","timestamp":1589200358000},"page":"8-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Multiple myeloma: Current and future management in the aging population"],"prefix":"10.1016","volume":"138","author":[{"given":"Despina","family":"Fotiou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meletios Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.maturitas.2020.04.015_bib0005","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.maturitas.2020.04.015_bib0010","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2014-10-609461","article-title":"Future distribution of multiple myeloma in the United States by sex, age, and race\/ethnicity","volume":"125","author":"Rosenberg","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.maturitas.2020.04.015_bib0015","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.maturitas.2020.04.015_bib0020","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.maturitas.2020.04.015_bib0025","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1600-0609.2005.00532.x","article-title":"Multiple myeloma in elderly patients: prognostic factors and outcome","volume":"75","author":"Anagnostopoulos","year":"2005","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.maturitas.2020.04.015_bib0030","first-page":"3152","article-title":"Vulnerability Variables Among Octagenarians Myeloma Patients: A Single -Center Analysis in 110 Patients, ASH 2017","author":"Gavriatopoulou","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.maturitas.2020.04.015_bib0035","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/gerona\/glt162","article-title":"Heterogeneity in healthy aging","volume":"69","author":"Lowsky","year":"2014","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"issue":"13","key":"10.1016\/j.maturitas.2020.04.015_bib0040","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.maturitas.2020.04.015_bib0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-018-0142-9","article-title":"Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)","author":"Larocca","year":"2018","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.maturitas.2020.04.015_bib0050","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.maturitas.2020.04.015_bib0055","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/bcj.2011.34","article-title":"Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score","volume":"1","author":"Kleber","year":"2011","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.maturitas.2020.04.015_bib0060","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.clml.2013.03.013","article-title":"Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome","volume":"13","author":"Kleber","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"3","key":"10.1016\/j.maturitas.2020.04.015_bib0065","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jgo.2018.10.010","article-title":"Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older","volume":"10","author":"Murillo","year":"2019","journal-title":"J. Geriatr. Oncol."},{"issue":"3","key":"10.1016\/j.maturitas.2020.04.015_bib0070","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jgo.2018.05.015","article-title":"Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant","volume":"10","author":"Rosko","year":"2019","journal-title":"J. Geriatr. Oncol."},{"issue":"1","key":"10.1016\/j.maturitas.2020.04.015_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jgo.2016.04.001","article-title":"Management of multiple myeloma in older adults: gaining ground with geriatric assessment","volume":"8","author":"Wildes","year":"2017","journal-title":"J. Geriatr. Oncol."},{"issue":"5","key":"10.1016\/j.maturitas.2020.04.015_bib0080","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/jgs.15715","article-title":"Geriatric assessment in older adults with multiple myeloma","volume":"67","author":"Wildes","year":"2019","journal-title":"J. Am. Geriatr. Soc."},{"issue":"15","key":"10.1016\/j.maturitas.2020.04.015_bib0085","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.maturitas.2020.04.015_bib0090","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.clml.2013.07.003","article-title":"Multiple myeloma international staging system: \u201cstaging\u201d or simply \u201caging\u201d system?","volume":"13","author":"Bataille","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"26","key":"10.1016\/j.maturitas.2020.04.015_bib0095","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.maturitas.2020.04.015_bib0100","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1056\/NEJMsa012528","article-title":"Understanding the treatment preferences of seriously ill patients","volume":"346","author":"Fried","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2020.04.015_bib0105","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/EDBK_239067","article-title":"Approach to the older adult with multiple myeloma","volume":"39","author":"Mina","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"11","key":"10.1016\/j.maturitas.2020.04.015_bib0110","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1038\/s41375-018-0072-6","article-title":"Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role","volume":"32","author":"Rodriguez-Otero","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.maturitas.2020.04.015_bib0115","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41375-019-0595-5","article-title":"The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial","volume":"34","author":"Pawlyn","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.maturitas.2020.04.015_bib0120","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2012.067058","article-title":"Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials","volume":"98","author":"Palumbo","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.maturitas.2020.04.015_bib0125","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma","volume":"31","author":"San Miguel","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"30","key":"10.1016\/j.maturitas.2020.04.015_bib0130","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2016.66.7295","article-title":"Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial","volume":"34","author":"Hulin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2020.04.015_bib0135","series-title":"Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) V Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM)","author":"Facon","year":"2017"},{"issue":"10068","key":"10.1016\/j.maturitas.2020.04.015_bib0140","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.maturitas.2020.04.015_bib0145","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, Melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.maturitas.2020.04.015_bib0150","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.maturitas.2020.04.015_bib0155","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1038\/bcj.2016.68","article-title":"Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up","volume":"6","author":"Biran","year":"2016","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.maturitas.2020.04.015_bib0160","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood-2018-99-111796","article-title":"Efficacy and Feasibility of Dose\/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study","volume":"132","author":"Larocca","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.maturitas.2020.04.015_bib0165","first-page":"230","article-title":"Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Kumar","year":"2017","journal-title":"J. Compr. Canc. Netw."},{"issue":"suppl_4","key":"10.1016\/j.maturitas.2020.04.015_bib0170","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann. Oncol."},{"issue":"15","key":"10.1016\/j.maturitas.2020.04.015_bib0175","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.2009.25.4250","article-title":"Importance of achieving a complete response in multiple myeloma, and the impact of novel agents","volume":"28","author":"Chanan-Khan","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.maturitas.2020.04.015_bib0180","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrclinonc.2014.239","article-title":"Minimal residual disease in multiple myeloma: bringing the bench to the bedside","volume":"12","author":"Mailankody","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.maturitas.2020.04.015_bib0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.04.004","article-title":"D. the, Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation","volume":"62","author":"Merz","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.maturitas.2020.04.015_bib0190","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3324\/haematol.2017.181339","article-title":"Melphalan 140 mg\/m(2) or 200 mg\/m(2) for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party","volume":"103","author":"Auner","year":"2018","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.maturitas.2020.04.015_bib0195","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","article-title":"Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial","volume":"104","author":"Palumbo","year":"2004","journal-title":"Blood"},{"issue":"9594","key":"10.1016\/j.maturitas.2020.04.015_bib0200","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.maturitas.2020.04.015_bib0205","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1080\/10428194.2016.1233542","article-title":"Autologous stem cell transplantation in elderly patients with multiple myeloma: evaluation of its safety and efficacy","volume":"58","author":"Stettler","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"7","key":"10.1016\/j.maturitas.2020.04.015_bib0210","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.bbmt.2017.03.012","article-title":"In-Hospital Mortality and Post-Transplantation Complications in Elderly Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Population-Based Study","volume":"23","author":"Sanchez","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.maturitas.2020.04.015_bib0215","author":"Straka","year":"2012"},{"issue":"22","key":"10.1016\/j.maturitas.2020.04.015_bib0220","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.maturitas.2020.04.015_bib0225","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1200\/JCO.2012.46.2598","article-title":"Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myelome experience","volume":"31","author":"Avet-Loiseau","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.maturitas.2020.04.015_bib0230","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.15261","article-title":"A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","author":"O\u2019Donnell","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.maturitas.2020.04.015_bib0235","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1182\/blood-2016-03-707596","article-title":"Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma","volume":"128","author":"Avet-Loiseau","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.maturitas.2020.04.015_bib0240","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2012.075051","article-title":"Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials","volume":"98","author":"Bringhen","year":"2013","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.maturitas.2020.04.015_bib0245","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2015-11-679415","article-title":"Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma","volume":"127","author":"Zweegman","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.maturitas.2020.04.015_bib0250","author":"Zweegman","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.maturitas.2020.04.015_bib0255","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.maturitas.2020.04.015_bib0260","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.14549","article-title":"Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study","volume":"177","author":"Dimopoulos","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"14","key":"10.1016\/j.maturitas.2020.04.015_bib0265","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.maturitas.2020.04.015_bib0270","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.maturitas.2020.04.015_bib0275","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.maturitas.2020.04.015_bib0280","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.maturitas.2020.04.015_bib0285","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","author":"Shah","year":"2020","journal-title":"Leukemia"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512220302450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512220302450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:15:47Z","timestamp":1759914947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512220302450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":57,"alternative-id":["S0378512220302450"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2020.04.015","relation":{},"ISSN":["0378-5122"],"issn-type":[{"value":"0378-5122","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple myeloma: Current and future management in the aging population","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2020.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}